Combination of anti-PD-1/PD-L1 antibodies with chemotherapy or CTL4 antibodies for first-line treatment of advanced lung cancer.

Abstract

e20538 Background: Checkpoint inhibitors showed satisfactory efficacy in treating lung cancer. We conducted this meta-analysis to explore the therapeutic efficacy and safety of anti-PD-1/PD-L1 antibodies combine with chemotherapy or CTL4 antibodies as first-line treatment on advanced lung cancer. Methods: A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, the conference abstracts and so on. The pooled ORR, 6-month progression-free survival rate (PFSR6m), and 1-year overall survival rate (OSR1y) were calculated and compared. 9 trials were included in this meta-analysis. Results: Our analyses demonstrated the pooled ORR and DCR of anti-PD-1/PD-L1 antibodies combine with chemotherapy for non-small-cell lung cancer were 48.0% (40.2–56.0 %) and 84.8 % (78.1– 89.7%), respectively. The pooled OR and DCR of anti-PD-1/PD-L1 antibodies combine with chemotherapy for small-cell lung cancer were 42.9% (18.5–71.2 %) and 73.6 % (32.8–94.1%), respectively. The pooled PFSR6m of anti-PD-1/PD-L1 antibodies combine with chemotherapy for NSCLC and SCLC were 62.9% (46.3–79.6%) and 27.6 % (18.9–36.2 %), respectively. The OSR1y of anti-PD-1/PD-L1 antibodies combine with chemotherapy for NSCLC and SCLC were 70.1 % (57.4%-82.8 %) and 32.0 % (25.2–38.9 %). In addition, the pooled ORR and DCR for anti-PD-1/PD-L1 antibodies plus CTL4 antibodies treatment group was 29.6% (11.4%-657.8%) and 48.7% (16.8%-81.7%), respectively. Conclusions: Anti-PD-1/PD-L1 antibody plus chemotherapy can serve as a promising treatment option for lung cancer. While patients treated anti-PD-1/PD-L1 antibodies plus CTL4 antibodies may benefit less compare with anti-PD-1/PD-L1 antibodies combine with chemotherapy. Encouraging activity with tolerable adverse effect was observed.